Clinical trials: Hemostatic Agents
Refractory or Relapsed Multiple Myeloma
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.
- Trial name
- NCT03716856
- Testing
- CAR-BCMA T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 11 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Myelodysplastic Syndromes, Leukemia Myeloid Acute
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
This is a post-authorization, retrospective multicentre observational nationwide study (PAS-OD). It will be conducted by reviewing medical records and database of patients who participated in the validation of the psychometric…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell
- Trial name
- NCT02842229
- Where
- 15 sites in Spain
- Volunteers
- 117 people
- Sponsor
- Celgene
Intraoperative Bleeding, Liver Diseases
GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery
This is a pre-market, prospective, randomized (1:1), multicenter, pivotal clinical investigation. The purpose of this investigation is to determine the clinical performance of GATT-Patch as compared with SURGICEL® Original for…
- Conditions
- Intraoperative Bleeding, Liver Diseases, Gallbladder Diseases, Hemorrhage, Surgical
- Trial name
- NCT05900037
- Testing
- GATT-Patch, SURGICEL® Original
- Where
- 6 sites in United States
- Volunteers
- 53 people
- Sponsor
- GATT Technologies BV
Multiple Myeloma
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CS1 cCAR in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT04156269
- Testing
- BCMA-CS1 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- iCell Gene Therapeutics
Multiple Myeloma
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received…
- Trial name
- NCT01029054
- Testing
- carfilzomib, lenalidomide plus dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment
- Trial name
- GMMG-HD6 (NCT02495922)
- Testing
- elotuzumab, Lenalidomide, Bortezomib
- Where
- 68 sites in Germany
- Volunteers
- 564 people
- Sponsor
- University of Heidelberg Medical Center
Multiple Myeloma
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.
- Trial name
- NCT03217812
- Testing
- Velcade, Melphalan, Prednisone
- Where
- 44 sites in China, Hong Kong and 3 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Hyperfibrinolysis, Cesarean Section Complications
The Incidence of Hyperfibrinolysis During Vaginal Delivery and Cesarean Section
This study aims to find out if there are common major changes in coagulation immediately after delivery of the newborn during Cesarean (C) -section and vaginal birth.
- Conditions
- Hyperfibrinolysis, Cesarean Section Complications, Coagulation Defect; Bleeding, Peripartum Haemorrhage
- Trial name
- NCT05975112
- Testing
- Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge
- Where
- Austria
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Leukemia, Lymphoma
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B-cell derived malignancies.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT02954445
- Testing
- Anti-BCMA-CAR-transduced T cells
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Southwest Hospital, China
Relapsed or Refractory Multiple Myeloma
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in…
- Trial name
- NCT06055075
- Testing
- Forimtamig, Carfilzomib, Daratumumab
- Where
- 8 sites in Australia, Canada and 4 more
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT04162119
- Testing
- BCMA-PD1-CART Cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
Multiple Myeloma Patient Registry
The purpose of this study is to document the participants characteristics, disease burden, and clinical management of participants in the United States who are treated for relapsed multiple myeloma in routine medical practice…
- Trial name
- NCT03180853
- Where
- 69 sites in United States
- Volunteers
- 85 people
- Sponsor
- Janssen Scientific Affairs, LLC
Multiple Myeloma
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb).
- Trial name
- DREAMM12 (NCT04398745)
- Testing
- Belantamab mafodotin
- Where
- 4 sites in Greece, South Korea
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and bortezomib improves the progression free survival and the response rate compared to historical controls of fludarabine and melphalan alone.
- Trial name
- Flu-Mel-Vel (NCT01453101)
- Testing
- Fludarabine monophosphate, melphalan, Bortezomib
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Hackensack Meridian Health
Hemorrhage
SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
This is a prospective, single arm, multicentre, multispecialty, post market, clinical study evaluating SURGICEL Powder as an adjunct to achieve haemostasis (control bleeding) when conventional methods of control are impractical…
- Trial name
- NCT03762200
- Testing
- SURGICEL Powder
- Where
- 8 sites in Belgium, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Ethicon, Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by…
- Trial name
- NCT00317811
- Testing
- ascorbic acid, bortezomib, melphalan
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Oncotherapeutics
Waldenström's Macroglobulinemia (WM)
Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia
Current retrospective studies have demonstrated that achieving deep remission following treatment for Waldenström's macroglobulinemia (WM) correlates with prolonged survival.
- Trial name
- BRZ-WM (NCT06942507)
- Testing
- Zanubrutinib, Bendamustine + Rituximab
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Peking Union Medical College Hospital
Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
Trial for patients with refractory multiple myeloma after failure of at least two treatment regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib (LGX818 in) combination with…
- Trial name
- GMMG-BIRMA (NCT02834364)
- Testing
- Encorafenib, Binimetinib
- Where
- 7 sites in Germany
- Volunteers
- 12 people
- Sponsor
- University of Heidelberg Medical Center
Multiple Myeloma
Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib
Clinical trial with a pharmaceutical specialty in a new combination. Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with multiple treatment-resistant or relapsing myeloma who have…
- Trial name
- POCODEX (NCT04243109)
- Testing
- Pomalidomide + Cyclophosphamide + Dexamethasone
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Multiple Myeloma
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability of fluphenazine in patients with advanced multiple myeloma. The study will also describe the efficacy of this drug.
- Trial name
- NCT00821301
- Testing
- Fluphenazine HCl
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Immune Control
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.